Home › Metastatische kanker › Tennessee › Nashville
Metastatische kanker klinische studies in Nashville, TN
70 studies voor Metastatische kanker zoeken deelnemers op locaties in en rond Nashville (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RekruterenFase 1/2
- Avenzo Therapeutics Recruiting Site, Nashville
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RekruterenFase 3
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology, Nashville
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruterenFase 2
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruterenFase 1
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruterenFase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RekruterenFase 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekruterenFase 1
- Sarah Cannon Research Institute (SCRI), Nashville
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RekruterenFase 1
- SCRI Oncology Partners, Nashville
A Study of ASP3082 in Adults With Advanced Solid Tumors
RekruterenFase 1
- Vanderbilt University Medical Center, Nashville
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RekruterenFase 2/3
- Henry-Joyce Cancer Clinic, Nashville
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
RekruterenFase 1
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RekruterenFase 3
- Henry-Joyce Cancer Clinic, Nashville
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekruterenFase 3
- Research Site, Nashville
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RekruterenFase 2/3
- Henry-Joyce Cancer Clinic, Nashville
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
RekruterenFase 1
- SCRI Oncology Partners, Nashville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruterenFase 3
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology, Nashville
- Tennessee Oncology, PLLC - Saint Thomas West, Nashville
- en nog 3
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
RekruterenFase 1/2
- Sarah Cannon Research Institute, Nashville
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekruterenFase 3
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekruterenFase 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RekruterenFase 3
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruterenFase 1/2
- Sarah Cannon Research Institue, Nashville
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
RekruterenFase 1
- Tennessee Oncology PLLC, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
RekruterenFase 1/2
- Tennessee Oncology, PLLC, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RekruterenFase 1/2
- Sarah Cannon Research Institute, Nashville
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekruterenFase 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC- Elliston Place Plaza, Nashville
- en nog 11
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
RekruterenFase 1/2
- SCRI Oncology Partners, Nashville
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RekruterenFase 1/2
- Clinical Study Site, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RekruterenFase 1
- Sarah Cannon Research Center, Nashville
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
RekruterenFase 3
- Research Site, Nashville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekruterenFase 3
- Tennessee Oncology, Nashville
- USO - US Oncology Research Network, Nashville
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
RekruterenFase 2
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
RekruterenFase 1/2
- Sarah Cannon Research Institute - Tennessee Oncology, Nashville
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RekruterenFase 1
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekruterenFase 2
- Vanderbilt-Ingram Cancer Center, Nashville
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RekruterenFase 1
- Sarah Cannon and HCA Research Institute, Nashville
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
RekruterenFase 2
- Research Site, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekruterenFase 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
RekruterenFase 1/2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RekruterenFase 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RekruterenFase 3
- Research Site, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RekruterenFase 1
- Investigative Site #102, Nashville
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RekruterenFase 1
- SCRI Oncology Partners, Nashville
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Sara Cannon Research Institute Tennessee, Nashville
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
RekruterenFase 1
- Exelixis Clinical Site #3, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
CT-95 in Advanced Cancers Associated With Mesothelin Expression
RekruterenFase 1
- Context Investigational Site, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RekruterenFase 1
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RekruterenFase 1
- Sarah Cannon Research Institute, Nashville
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RekruterenFase 1
- Vanderbilt University Medical Center, Nashville
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
RekruterenFase 1/2
- Sarah Cannon, Nashville
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
RekruterenFase 1/2
- SCRI Oncology Partners, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RekruterenFase 1/2
- Sarah Cannon Research Institute, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
RekruterenVroege fase 1
- Vanderbilt University Medical Center, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RekruterenFase 1/2
- SCRI Oncology Partners, Nashville
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RekruterenFase 2/3
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic), Nashville
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RekruterenFase 1
- SCRI Oncology Partners, Nashville
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
RekruterenFase 1
- SCRI Oncology Partners, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekruterenFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
RekruterenFase 3
- Vanderbilt University Medical Center, Nashville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
RekruterenFase 1
- Urology Associates PC, Nashville
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
RekruterenFase 1
- Vanderbilt-Ingram Cancer Center, Nashville
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
RekruterenFase 1
- SCRI Oncology Partners, Nashville
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RekruterenFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
RekruterenFase 1/2
- SCRI Oncology Partners, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Nashville
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
RekruterenFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
Metastatische kanker studies in andere steden
- Houston, TX104 studies
- New York City, NY93 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
- Seattle, WA39 studies
Andere studies in Nashville
- Niet-kleincellige longkanker97 studies
- Borstkanker81 studies
- Colorectale kanker69 studies
- Kanker (alle vormen)65 studies
- Eierstokkanker49 studies
- Prostaatkanker43 studies
- Longkanker40 studies
- Plaveiselcelcarcinoom van hoofd en hals39 studies
- Aldermeesklierkanker39 studies
- Endometriumkanker38 studies
- Melanoom33 studies
- Multipel myeloom32 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.